Volume 57, Issue 2 pp. 250-253
Pharmacology and Therapeutics

Isotretinoin treatment for folliculitis decalvans: a retrospective case-series study

Berna Aksoy MD

Corresponding Author

Berna Aksoy MD

School of Medicine, Dermatology Department, Bahcesehir University, Istanbul, Turkey

Correspondence

Berna Aksoy, md

VM Medicalpark Hospital

Ovacık District, Beside D-100 Highway

No: 36 Basiskele / Kocaeli

Turkey

E-mails: [email protected], [email protected]

Search for more papers by this author
Asli Hapa MD

Asli Hapa MD

Dermatology Clinic, Buca Seyfi Demirsoy State Hospital, Izmir, Turkey

Search for more papers by this author
Emine Mutlu MD

Emine Mutlu MD

Faculty of Medicine, Department of Dermatology, Celal Bayar University, Manisa, Turkey

Search for more papers by this author
First published: 04 January 2018
Citations: 19
The study protocol was approved by the local ethics committee (Kocaeli University, Kocaeli, Turkey)
This study was presented as a poster at the 26th National Dermatology Congress, Antalya, Turkey, 2016 (awarded second best poster), and at the 25th EADV Congress, Vienna, Austria, in 2016.
Funding: There is no funding source for the study.
Conflict of interest: The authors declare there are no conflicts of interest, any current or past – financial or otherwise – related to the material presented in this manuscript.

Abstract

Background

The literature includes only a few reports of oral isotretinoin for the treatment of folliculitis decalvans (FD). This study aimed to determine the most effective dose and duration of oral isotretinoin monotherapy for achieving remission in FD patients.

Methods

This retrospective case series study included FD patients that were treated with oral isotretinoin. Patient demographics, clinical characteristics, and treatment details were obtained from the patients’ medical records. Patients were contacted via telephone after treatment was completed and asked about any relapses, time period of relapses, and the long-term effects of the treatment.

Results

The study included 39 male patients with a mean age of 37.9 ± 15.5 years. All of the patients received oral isotretinoin 0.1–1.02 mg/kg/day (10–90 mg/day) for a median duration of 2.5 months (range: 1–8 months). In all, 82.0% of patients healed after the treatment. Patients that received oral isotretinoin ≥0.4 mg/kg/day for ≥3 months responded better, and 66% of them never relapsed.

Conclusion

Contrary to general belief, oral isotretinoin monotherapy resulted in complete response in the majority of patients in this study. Based on this finding, we think oral isotretinoin ≥0.4 mg/kg/day should be given for ≥3 months to minimize the likelihood of relapse. In addition, we think oral isotretinoin monotherapy should be considered a promising treatment alternative for FD that warrants further research.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.